Loading...
CRON logo

Cronos Group Inc.TSX:CRON 株式レポート

時価総額 CA$1.6b
株価
n/a
1Y30.5%
7D6.5%
1D3.6%
ポートフォリオ価値
​
表示

Cronos Group Inc.

TSX:CRON 株式レポート

時価総額：CA$1.6b

Cronos Group（CRON）株式概要

カンナビノイド企業であるクロノス・グループ社は、カナダ、イスラエル、および国際的な大麻製品の栽培、生産、流通、販売に従事している。 詳細

CRON ファンダメンタル分析
スノーフレーク・スコア
評価3/6
将来の成長1/6
過去の実績5/6
財務の健全性6/6
配当金0/6

報酬

当社が推定した公正価値より43.2%で取引されている

収益は年間5.18%増加すると予測されています

過去1年間で収益は278.5%増加しました

リスク分析

今後3年間の収益は年平均0.9%減少すると予測されている。


CRON Community Fair Values

Create Narrative

See what 17 others think this stock is worth. Follow their fair value or set your own to get alerts.

Analyst Price Targets

View all narratives

Cronos Group Inc. 競合他社

価格と性能

株価の高値、安値、推移の概要Cronos Group
過去の株価
現在の株価CA$4.62
52週高値CA$4.99
52週安値CA$3.23
ベータ1.28
1ヶ月の変化5.72%
3ヶ月変化20.00%
1年変化30.51%
3年間の変化57.14%
5年間の変化-38.48%
IPOからの変化456.63%

最新ニュース

ナラティブ更新 • Aug 09

CRON: Buybacks And Higher Multiple Will Support A Stronger Outlook

Analysts have increased their Cronos Group price target by CA$1 to CA$6, reflecting updated assumptions regarding fair value, discount rate, growth, and margins following recent research updates. What’s in the News for Cronos Group Cronos Group announced a share repurchase program that allows the company to buy back up to 18,712,918 shares for $50 million.

Recent updates

ナラティブ更新 • Aug 09

CRON: Buybacks And Higher Multiple Will Support A Stronger Outlook

Analysts have increased their Cronos Group price target by CA$1 to CA$6, reflecting updated assumptions regarding fair value, discount rate, growth, and margins following recent research updates. What’s in the News for Cronos Group Cronos Group announced a share repurchase program that allows the company to buy back up to 18,712,918 shares for $50 million.
ナラティブ更新 • Jun 28

CRON: Partial Rescheduling And Buybacks Will Support A Stronger Outlook

Analysts have raised their Cronos Group price target by CA$0.50 to CA$5.50, citing revised assumptions around higher projected revenue growth, a different discount rate, and updated margin and P/E expectations following recent research commentary and a more favorable view on partial cannabis re scheduling. Analyst Commentary Recent research on Cronos Group highlights how shifting views on cannabis policy and updated valuation work are feeding into more constructive analyst sentiment on the stock.
ナラティブ更新 • Jun 14

CRON: Brand Strength And Rescheduling Tailwinds Will Support Future Upside

Analysts have lifted their CA$ price target on Cronos Group, with an updated fair value of CA$4.68 compared with the prior CA$4.24. This reflects refreshed views on revenue growth, margins, discount rates and future P/E assumptions following recent Street research, including the CA$1 target increase at TD Securities and supportive commentary around partial cannabis rescheduling from Roth Capital.
ナラティブ更新 • May 31

CRON: Partial Rescheduling Expectations Will Constrain Future Earnings Power

Analysts have raised Cronos Group's CA$ price target by CA$1, citing updated expectations around revenue growth, margins and future P/E assumptions, as well as recent Street research that includes a CA$1 target increase at TD Securities and favorable perspectives on partial cannabis re-scheduling. Analyst Commentary Recent Street commentary around Cronos Group has focused on how updated revenue expectations, margin trajectories and P/E assumptions feed into revised valuation frameworks.
ナラティブ更新 • May 12

CRON: Partial Rescheduling And Brand Execution Will Shape Lean Profit Outlook

Analysts have lifted their fair value estimate for Cronos Group from CA$3.19 to CA$3.45, citing recent initiation with a CA$4.50 price target and the view that branded positioning, a lean cost base, and potentially favorable regulatory shifts could support higher long term profitability and a lower future P/E assumption. Analyst Commentary Recent commentary around Cronos Group has focused on brand strength, cost discipline, and the potential impact of regulatory changes in key markets.
ナラティブ更新 • Apr 25

CRON: Partial Rescheduling Hopes Will Test Lean Cost Base Execution

Analysts have raised their Cronos Group price target to CA$4.50, citing expectations for slightly stronger revenue growth, modestly better profit margins, and a lower assumed future P/E, following recent bullish coverage and a favorable view on partial cannabis rescheduling. Analyst Commentary Recent research coverage on Cronos Group has centered on how potential regulatory shifts and brand positioning could influence the company’s path to improved profitability and valuation.
ナラティブ更新 • Apr 11

CRON: Canadian Brand Strength And Lean Cost Base Will Support Future Upside

Analysts have reset their price target for Cronos Group to CA$4.50, reflecting fresh coverage that highlights the company’s established Canadian brands, its focus on scaling revenue with a lean cost base, and cultivation practices that are expected to support profitability trends. Analyst Commentary Recent coverage frames Cronos Group as a company with established Canadian brands and a focus on keeping its cost base lean while scaling revenue.
ナラティブ更新 • Mar 28

CRON: Lean Cost Base And Brand Execution Will Shape Future Earnings Potential

Analysts have lifted their average price target for Cronos Group to CA$4.50, citing expectations for faster top line expansion, a leaner cost base and stronger profitability potential supported by the company's established Canadian cannabis brands and cultivation practices. Analyst Commentary Recent Street research has framed Cronos Group as a branded cannabis operator with established products in Canada and an emphasis on scaling revenue while keeping operating costs in check.
ナラティブ更新 • Mar 13

CRON: Canadian Brand Strength And Rescheduling Shift Will Support Future Upside

Analysts have lifted their CA$ price target on Cronos Group, citing the company's Canadian cannabis brands, expectations for better profitability as revenue grows against a lean cost base, and confidence in its cultivation practices as key supports for the higher valuation range. Analyst Commentary Bullish Takeaways Bullish analysts highlight Cronos Group's portfolio of Canadian cannabis brands as a key support for the higher CA$ valuation range, arguing that strong consumer recognition can help sustain revenue as the company scales.
ナラティブ更新 • Feb 27

CRON: Canadian Brand Strength And Rescheduling Shift Will Reshape Risk Reward Profile

Analysts have lifted their fair value estimate for Cronos Group to CA$4.24 from CA$3.95, pointing to higher assumed revenue growth and a lower future P/E multiple. They are factoring in recent bullish coverage highlighting the company’s established Canadian cannabis brands, lean cost base, and cultivation practices.
ナラティブ更新 • Feb 13

CRON: Rescheduling Shift Will Expose Execution Risks And Restrain Earnings Upside

Analysts have lifted their CA$ fair value estimate for Cronos Group to CA$3.19, citing Street research that points to slightly higher expected revenue growth, modestly stronger profit margins, and a marginally lower future P/E assumption that together support a more constructive long term outlook. Analyst Commentary While the higher CA$3.19 fair value estimate reflects a more constructive stance on Cronos Group, not all research is leaning in the same direction.
ナラティブ更新 • Jan 30

CRON: Rescheduling Shift And Product Expansion Will Shape A Balanced Earnings Outlook

Analysts have raised their price target on Cronos Group by a small amount to reflect updated assumptions for slightly higher revenue growth, a modestly stronger profit margin, and a marginally higher future P/E multiple. Analyst Commentary While some research points to a constructive view on Cronos Group, bearish analysts highlight a set of risks that could limit upside and keep the stock more range bound.
ナラティブ更新 • Jan 16

CRON: Rescheduling Policy Shift Will Temper Optimism On Future Earnings Profile

Analysts have raised their price target for Cronos Group to US$3.19 from US$2.90, pointing to updated assumptions around slightly higher discount rates, more conservative revenue growth and a modestly stronger profit margin profile, alongside a similar forward P/E outlook. What's in the News President Trump directed the Attorney General to complete the rulemaking process to reschedule marijuana to Schedule III of the Controlled Substances Act, which directly touches U.S. cannabis policy and mentions Cronos Group among other publicly traded peers in the sector (Marijuana Herald).
分析記事 • Dec 13

Cronos Group Inc. (TSE:CRON) Stock Rockets 29% As Investors Are Less Pessimistic Than Expected

Cronos Group Inc. ( TSE:CRON ) shareholders have had their patience rewarded with a 29% share price jump in the last...
ナラティブ更新 • Sep 04

GrowCo Capacity And Global Markets Will Unlock Potential

The Consensus Analyst Price Target for Cronos Group has increased to CA$3.95, primarily reflecting a notable rise in the company's Future P/E multiple despite stable revenue growth expectations. What's in the News President Trump is considering reclassifying marijuana as a less dangerous drug, which could ease restrictions and benefit cannabis companies such as Cronos Group (The Wall Street Journal).
分析記事 • Aug 15

Cronos Group Inc.'s (TSE:CRON) 26% Share Price Surge Not Quite Adding Up

Cronos Group Inc. ( TSE:CRON ) shareholders would be excited to see that the share price has had a great month, posting...
User avatar
新しいナラティブ • Apr 30

GrowCo Expansion Will Boost Operations But Strain Cash Flow

Investment in GrowCo and advancements in cannabis genetics are set to improve efficiency, enhance profitability, and strengthen market penetration.
分析記事 • May 31

We're Interested To See How Cronos Group (TSE:CRON) Uses Its Cash Hoard To Grow

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
分析記事 • Apr 01

Cronos Group Inc.'s (TSE:CRON) P/S Is Still On The Mark Following 29% Share Price Bounce

The Cronos Group Inc. ( TSE:CRON ) share price has done very well over the last month, posting an excellent gain of...
分析記事 • Mar 02

We Think Cronos Group (TSE:CRON) Can Afford To Drive Business Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
分析記事 • Feb 02

Revenues Tell The Story For Cronos Group Inc. (TSE:CRON)

When you see that almost half of the companies in the Pharmaceuticals industry in Canada have price-to-sales ratios (or...
分析記事 • Nov 09

Companies Like Cronos Group (TSE:CRON) Are In A Position To Invest In Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

株主還元

CRONCA PharmaceuticalsCA 市場
7D6.5%-1.2%-1.6%
1Y30.5%6.9%21.9%

業界別リターン: CRON過去 1 年間で6.9 % の収益を上げたCanadian Pharmaceuticals業界を上回りました。

リターン対市場: CRON過去 1 年間で21.9 % の収益を上げたCanadian市場を上回りました。

価格変動

Is CRON's price volatile compared to industry and market?
CRON volatility
CRON Average Weekly Movement6.0%
Pharmaceuticals Industry Average Movement8.1%
Market Average Movement9.1%
10% most volatile stocks in CA Market16.1%
10% least volatile stocks in CA Market3.6%

安定した株価: CRON 、 Canadian市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。

時間の経過による変動: CRONの 週次ボラティリティ ( 6% ) は過去 1 年間安定しています。

会社概要

設立従業員CEO（最高経営責任者ウェブサイト
n/a610Mike Gorensteinthecronosgroup.com

カンナビノイド企業であるクロノス・グループ社は、カナダ、イスラエル、および国際的な大麻製品の栽培、生産、流通、マーケティングに従事している。同社はSpinach、Lord Jones、PEACE NATURALSのブランド名でドライフラワー、プレロール、オイル、ヴェポライザー、エディブル、大麻チンキを提供している。本拠地はカナダのステイナー。

Cronos Group Inc. 基礎のまとめ

Cronos Group の収益と売上を時価総額と比較するとどうか。
CRON 基礎統計学
時価総額CA$1.64b
収益（TTM）CA$97.90m
売上高(TTM)CA$250.53m
17.4x
PER（株価収益率
6.8x
P/Sレシオ

CRON は割高か？

公正価値と評価分析を参照

収益と収入

最新の決算報告書（TTM）に基づく主な収益性統計
CRON 損益計算書（TTM）
収益US$179.09m
売上原価US$102.05m
売上総利益US$77.04m
その他の費用US$7.06m
収益US$69.98m

直近の収益報告

Jun 30, 2026

次回決算日

該当なし

一株当たり利益（EPS）0.19
グロス・マージン43.02%
純利益率39.08%
有利子負債／自己資本比率0%

CRON の長期的なパフォーマンスは？

過去の実績と比較を見る

企業分析と財務データの現状

データ最終更新日（UTC時間）
企業分析2026/09/16 18:29
終値2026/09/16 00:00
収益2026/06/30
年間収益2025/12/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージデータタイムフレーム米国ソース例
会社財務10年
  • 損益計算書
  • キャッシュ・フロー計算書
  • 貸借対照表
アナリストのコンセンサス予想+プラス3年
  • 予想財務
  • アナリストの目標株価
市場価格30年
  • 株価
  • 配当、分割、措置
所有権10年
  • トップ株主
  • インサイダー取引
マネジメント10年
  • リーダーシップ・チーム
  • 取締役会
主な進展10年
  • 会社からのお知らせ

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

このレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。

シンプリー・ウォールストリート分析モデルを設計・構築した ご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

Cronos Group Inc. 4 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。16

アナリスト機関
Jesse PytlakATB Cormark Historical (Cormark Securities)
Vahan AjamianBeacon Securities Limited
Nadine SarwatBernstein